137 related articles for article (PubMed ID: 36859512)
1. Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients.
Donnette M; Osanno L; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Costello R; Caroline S; Ouafik L'; Ciccolini J; Fanciullino R
Cancer Chemother Pharmacol; 2023 Mar; 91(3):231-238. PubMed ID: 36859512
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
[TBL] [Abstract][Full Text] [Related]
3. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
[TBL] [Abstract][Full Text] [Related]
4. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
6. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
[TBL] [Abstract][Full Text] [Related]
7. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T; Furstoss N; Savy C; El Manaa W; Zerhouni M; Blot L; Calleja A; Dufies M; Dubois A; Ginet C; Mounier N; Garnier G; Raynaud S; Rohrlich PS; Peterlin P; Stamatoullas A; Chermat F; Fenaux P; Jacquel A; Robert G; Auberger P
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881723
[TBL] [Abstract][Full Text] [Related]
8. Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of azacitidine in rat plasma and its application to a bioavailability study.
Li D; Zhang T; Kou L; Zhang Y; Sun J; He Z
Molecules; 2013 Dec; 19(1):342-51. PubMed ID: 24378972
[TBL] [Abstract][Full Text] [Related]
9. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
[TBL] [Abstract][Full Text] [Related]
11. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
12. A pilot pharmacokinetic study of oral azacitidine.
Garcia-Manero G; Stoltz ML; Ward MR; Kantarjian H; Sharma S
Leukemia; 2008 Sep; 22(9):1680-4. PubMed ID: 18548103
[TBL] [Abstract][Full Text] [Related]
13. Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.
Ramsey HE; Oganesian A; Gorska AE; Fuller L; Arrate M; Boyd K; Keer H; Azab M; Savona MR
Target Oncol; 2020 Apr; 15(2):231-240. PubMed ID: 32222953
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
15. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
18. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T; Robert G; Mounier N; Karsenti JM; Dufies M; Puissant A; Jacquel A; Renneville A; Preudhomme C; Cassuto JP; Raynaud S; Luciano F; Auberger P
Oncotarget; 2012 Apr; 3(4):490-501. PubMed ID: 22577154
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
